UBS’s Accretive Health AH Stock Holding History

UBS’s Portfolio AH Stock Details AH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-200	Closed	-$2K	–	11389
2014 Q1	$2K	Sell	200 -200	-50%	-$1.77K	﹤0.01%	10151
2013 Q4	$4K	Buy	400 +100	+33%	+$861	﹤0.01%	9809
2013 Q3	$3K	Sell	300 -7,400	-96%	-$73.6K	﹤0.01%	9882
2013 Q2	$83K	Buy	+7,700	New	+$81K	﹤0.01%	6121

Other funds holding AH

JRP

Jasper Ridge Partners Menlo Park, California $4.49B AUM 18.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

RMC

Regis Management Company Menlo Park, California $331M AUM 14.13% 1-Year Est. Return

BCM

Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return

ECM

EII Capital Management New York $774K AUM 22.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MIM

Merion Investment Management Bay Harbor Islands, Florida $1.26M AUM 28.57% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

SCM

Stonebridge Capital Management Los Angeles, California $220M AUM

UBS's AH Position: Q2 2014 in Review

UBS sold out of Accretive Health (AH) in Q2 2014, closing a stake of 13,479 shares — an estimated $107K sold.

UBS first reported a position in AH in Q2 2013 and held it in 4 quarters. The position peaked at $1.57M in Q2 2013. 12 funds tracked by Wall St. Rank hold AH as of Q2 2014.

UBS reported no remaining Accretive Health position as of Q2 2014 after selling out during the quarter.
UBS sold 13,479 Accretive Health shares in Q2 2014, an estimated $107K.
UBS first reported a position in Accretive Health in Q2 2013 and held it in 4 quarters.
UBS's Accretive Health position peaked at $1.57M in Q2 2013.
12 funds tracked by Wall St. Rank held Accretive Health as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.